Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

Phase 1

Recruiting

Conditions: Urothelial Carcinoma Bladder
Bladder Cancer

Interventions: Radiation: Concurrent Immunotherapy and Radiation Therapy

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 10

Registration Number: NCT06586255

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis

Not Applicable

Not yet recruiting

Conditions: FAP
Familial Adenomatous Polyposis

Interventions: Dietary Supplement: R-1,3-Butanediol (30MG-A)
Dietary Supplement: Placebo
Dietary Supplement: R-1,3-Butanediol (10MG-A)
Dietary Supplement: R-1,3-Butanediol (20MG-B)
Dietary Supplement: R-1,3-Butanediol (20MG-A)
Dietary Supplement: R-1,3-Butanediol (10MG-B)

First Posted Date: 2024-08-29

Last Posted Date: 2024-08-29

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 30

Registration Number: NCT06578637

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Nudge Strategies for DPYD Testing in Patients With Gastrointestinal Cancers Treated With Fluoropyrimidines

Not Applicable

Conditions: Health Care Seeking Behavior
DPYD Gene Mutation
Gastrointestinal Cancer

Interventions: Other: Focus Group
Other: Discrete Choice

First Posted Date: 2024-08-19

Last Posted Date: 2025-06-26

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 160

Registration Number: NCT06559462

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Recruiting

Conditions: HER2-positive Metastatic Breast Cancer

Interventions: Diagnostic Test: CE-10-IVD

First Posted Date: 2024-08-13

Last Posted Date: 2025-06-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 200

Registration Number: NCT06551116

Locations: 🇺🇸
UNC Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
UPMC Hillman CC, Pittsburgh, Pennsylvania, United States

and more 25 locations

Using Surveys to Examine the Association of Exposure to ML Mortality Risk Predictions With Medical Oncologists' Prognostic Accuracy and Decision-making

Completed

Conditions: Oncology

Interventions: Other: Survey

First Posted Date: 2024-06-18

Last Posted Date: 2024-11-21

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 52

Registration Number: NCT06463977

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Phase 2

Recruiting

Conditions: Lymphoma, Non-Hodgkin
Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
High-grade B-cell Lymphoma
Refractory Diffuse Large B-cell Lymphoma
Relapsed Diffuse Large B Cell Lymphoma

Interventions: Drug: Epcoritamab

First Posted Date: 2024-06-13

Last Posted Date: 2025-03-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 31

Registration Number: NCT06458439

Locations: 🇺🇸
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Nudge to Gynecologic Oncology

Not Applicable

Active, not recruiting

Conditions: Peritoneal Cancer
Ovarian Cancer
Fallopian Tube Cancer

Interventions: Behavioral: Nudge

First Posted Date: 2024-06-11

Last Posted Date: 2024-11-29

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 20

Registration Number: NCT06451263

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer

Conditions: Ovarian Cancer
BRCA Mutation

First Posted Date: 2024-05-31

Last Posted Date: 2024-10-01

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 24

Registration Number: NCT06436248

Locations: 🇺🇸
Abramson Cancer Center, Philadelphia, Pennsylvania, United States

Physical Activity in Rectal Cancer Survivors

Not Applicable

Completed

Conditions: Rectosigmoid Cancer
Rectal Cancer

Interventions: Other: Physical Activity
Other: Survey
Behavioral: Telehealth Lifestyle Coaching

First Posted Date: 2024-05-30

Last Posted Date: 2024-05-30

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 20

Registration Number: NCT06435975

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

FAPI-74 PET/CT in Adults With Fibrosis

Phase 1

Recruiting

Conditions: Fibrosis (Morphologic Abnormality)

Interventions: Drug: [F-18]-FAPI-74

First Posted Date: 2024-05-14

Last Posted Date: 2025-01-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 45

Registration Number: NCT06413355

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy